Antidepressant-induced suicidality: An update

CNS Neuroscience and Therapeutics

Volumn 16, Issue 4, 2010, Pages 227-234

  Reeves, Roy R ^a,b   Ladner, Mark E ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Depression; SSRIs; Suicide

Indexed keywords

AMOXAPINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOSULEPIN; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

DEPRESSION; DISEASE EXACERBATION; FOLLOW UP; HUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUICIDE; UNITED STATES; CLASSIFICATION; FOOD AND DRUG ADMINISTRATION; META ANALYSIS (TOPIC); STATISTICS AND NUMERICAL DATA; TRENDS;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; META-ANALYSIS AS TOPIC; SUICIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954381293     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00160.x     Document Type: Review

References (68)

1. Moller HJ. Evidence for beneficial effects of antidepressants on suicidality in depressed patients: A systemic review. Eur Arch Psychiatry Clin Neurosci 2006 256 : 329 343.
2. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. PLoS Med 2008 5 : 260 268.
3. Moller HJ. Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirch et al. 2008. Eur Arch Psychiatry Clin Neurosci 2008 258 : 451 455.
4. Tang TZ, DeRubeis RJ, Hollon SD, et al. Personality change during depression treatment. Arch Gen Psychiatry 2009 66 : 1322 1330.
5. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004 292 : 338 343.
6. Culpepper L, Davidson JRT, Dietrich AJ, et al. Suicidality as a possible side effect of antidepressant treatment. Prim Care Companion J Clin Psychiatry 2004 6 : 79 86.
7. Reeves RR, Ladner ME. Antidepressant-induced suicidality: Implications for clinical practice. South Med J 2009 102 : 713 718.
8. Reeves RR, Brister JC. Serious suicide attempt with duloxetine treatment (letter). South Med J 2008 101 : 769.
9. Akiskal HS, Mallya G. Criteria for the "soft" bipolar spectrum: Treatment implications. Psychopharmacol Bull 1987 23 : 68 73.
10. Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol 1988 8 : 347 349.
11. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990 147 : 207 210. (Pubitemid 20060476)
12. Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. N Engl J Med 1991 324 : 420.
13. King RA, Riddle MA, Chappell PB, et al. Emergence of self-destructive phenomenon in children and adolescents during fluoxetine treatment. J Am Acad Child Adol Psychiatry 1991 30 : 329 332.
14. Wirsching WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia and suicidality: Is there a causal connection? Arch Gen Psychiatry 1992 49 : 580 581.
15. Aursnes I, Tvete IF, Gaasemyer J, Natvig B. Suicide attempts in clinical trials with paroxetine randominized against placebo. BMC Psychiatry 2005 3 : 14.
16. Healy D. Emergence of antidepressant induced suicidality. Prim Care Psychiatry 2000 6 : 23 28.
17. Beasley CM Jr., Dornself BE, Bosomworth JC, et al. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. BMJ 1991 303 : 685 692.
18. Khan A, Khan S, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: Analysis of FDA reports. Am J Psychiatry 2003 160 : 790 792.
19. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007 164 : 1029 1034.
20. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006 163 : 41 47.
21. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomized controlled trials submitted to the MHRA's safety review. BMJ 2005 330 : 385 388.
22. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006 63 : 1358 1367.
23. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006 26 : 203 207.
24. Seemuller F, Riedel M, Obermeier H, et al. The controversial link between antidepressants and suicidality risks in adults: Data from a naturalistic study on a large scale sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 2009 12 : 181 189.
25. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006 63 : 332 339.
26. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA 2007 297 : 1683 1696.
27. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006 163 : 813 821.
28. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomized controlled trials. BMJ 2005 330 : 396 399.
29. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009 339 : b2880. doi :.
30. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 1993 8 : 186 212.
31. Feuerstein TJ, Jackisch R. Why do some antidepressants promote suicide? Psychopharmacol 1980 90 : 422.
32. Goodman WK, Murphy TK, Storch EA. Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacol 2007 191 : 87 96.
33. Walkup J, Labellarte M. Complications of SSRI treatment. J Child Adolesc Psychopharmacol 2001 11 : 1 4.
34. Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: Fact or overinterpretation? CNS Spectr 2008 13 : 790 795.
35. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. J Clin Psychiatry 1991 52 : 491 493.
36. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: Systematic review. Br J Psychiatry 2009 194 : 483 490.
37. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007 164 : 1356 1363.
38. Baldessarini R. Current status of antidepressants: Clinical pharmacology and therapy. J Clin Psychiatry 1989 50 : 117 126.
39. Creaney W, Murray M, Healy D. Antidepressant induced suicidal ideation. Hum Psychopharmacol 1991 6 : 329 332.
40. Hoover CE. Additional case of suicidal ideation associated with fluoxetine. Am J Psychiatry 1990 147 : 1570 1571.
41. Harvey AT, Silkey BS, Kornstein SG, Clary CM. Acute worsening of chronic depression during a double-blind, clinical randomized trial of antidepressant efficacy: Differences by sex and menopausal status. J Clin Psychiatry 2007 68 : 951 958.
42. Henry C, Demotes-Mainard J. SSRIs, suicide, and violent behavior: Is there a need for a better definition of the depressive state? Curr Drug Safety 2006 1 : 59 62.
43. Benazzi F, Koukopoulos A, Akiskal HS. Toward a validation of a new definition of agitated depression as a bipolar mixed state (mixed depression). Eur Psychiatry 2004 19 : 85 90.
44. Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated "unipolar depression reconceptualized as a depressive mixed state: Implications for the antidepressant-suicide controversy. J Affect Disord 2005 85 : 245 258.
45. Bernert RA, Joiner TR Jr., Cukrowicz KC, et al. Suicidality and sleep disturbances. Sleep 2005 28 : 1135 1141.
46. Chellappa SL, Araujo JF. Sleep disorders and suicidal ideation in patients with depressive disorder. Psychiatry Res 2007 153 : 288 293.
47. Struve FA, Klein DF, Saraf KR. Electroencephalographic correlates of suicide ideation and attempts. Arch Gen Psychiatry 1972 27 : 363 365.
48. Iosifescu DV, Greenwald S, Devlin P, et al. Pretreatment frontal EEG changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand 2008 117 : 271 276.
49. Soloff PH, George A, Nathan RS, et al. Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry 1986 143 : 1603 1605.
50. Pohl R, Yeragani VK, Balon R, Lycaki H. The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry 1988 49 : 100 104.
51. Mann JJ, Arango V, Marzuk PM, et al. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br J Psychiatry Suppl 1989 155 (Suppl 8 7 14.
52. Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 1998 44 : 313 323.
53. Gross C, Zhuang X, Stark K, et al. Serotonin 1 A receptor acts during development to establish normal anxiety-like behavior in the adult. Nature 2002 416 : 396 400.
54. Tsai SJ. Possible involvement of the BDNF-dependent pathway in treatment-emergent suicidality or decreased response to antidepressants. Med Hypothesis 2005 65 : 942 946.
55. Perlis H, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003 54 : 879 883.
56. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapies 2004 59 : 5 12.
57. Smith EG. Association between antidepressant half-life and the risk of suicidal ideation or behavior among children and adolescents: Confirmatory analysis and research implications. J Affect Disord 2009 114 : 143 148.
58. Moller HJ. Is there evidence for negative effects of antidepressants on suicidality in depressive patients? Eur Arch Psychiatry Clin Neurosci 2006 256 : 476 496.
59. Reith DM, Edmonds L. Assessing the role of drugs in suicidal ideation and suicidality. CNS Drugs 2007 21 : 463 472.
60. Hall WD, Lucke J. How have the selective serotonin rekuptake inhibitor antidepressants affected suicide mortality? Aust N Zeal J Psychiatry 2006 40 : 941 950.
61. Libby AM, Brent DA, Morrato HD, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007 164 : 884 891.
62. Centers for Disease Control and Prevention. Suicide trends among youths and young adults aged 10-24 years: United States, 1990-2004. MMWR Morb Mortal Wkly Rep 2007 56 : 905 908.
63. Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2007 164 : 1198 1205.
64. Sussman N. FDA warnings and suicide rates: Unintended consequences. Prim Psychiatry 2008 15 : 22 23.
65. Wheeler BW, Gunnell D, Metcalfe C, et al. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: Ecological study. BMJ 2008 336 : 542 545.
66. Moller HJ, Baldwin DS, Goodwin G, et al. Do SSRIs or antidepressants in general increase suicidality? WPA Section On Pharmacopsychiatry: Consensus statement. Eur Arch Psychiatry Clin Neurosci 2008 258 (Suppl 3 3 23.
67. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008 165 : 42 50.
68. Rihmer Z, Akiskal H. Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affective Dis 2006 94 : 3 13.